特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
940592

遺伝子検査市場:世界市場の予測・分析 (用途別・技術別)、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)

Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2020 to 2024

出版日: | 発行: Howe Sound Research | ページ情報: 英文 429 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
遺伝子検査市場:世界市場の予測・分析 (用途別・技術別)、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)
出版日: 2020年06月05日
発行: Howe Sound Research
ページ情報: 英文 429 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、遺伝子検査の今後の技術進歩・市場成長の見通しについて分析し、技術的な概略や主な活用分野、今後の医療現場に及ぼす影響力、昨今の主な開発・製品上市の動き、主要企業のプロファイルと主力製品、今後の市場規模の動向見通し、地域別・用途別・技術別の詳細動向、新型コロナウイルス感染症 (Covid-19) 発生の影響、といった情報を取りまとめてお届けいたします。

目次

i. 遺伝子検査市場:戦略的状況分析とCovid-19の影響

ii. エグゼクティブ・マーケティング・販売・ビジネス開発スタッフ向け提言

iii. 経営コンサルタント・投資顧問向け提言

第1章 イントロダクション、市場の定義

第2章 市場概要

  • 市場参加者はさまざまな役割を果たす
    • サプライヤー/製薬企業
    • 独立系の検査室:専門別/難病
    • 独立系の検査室:国/地域別
    • 独立系の検査室:解析
    • 国営/公営の検査室
    • 病院検査室
    • 開業医検査室
    • DTC検査室
    • 独立系の遺伝子検査室
    • 監査機関
  • 遺伝子検査-種類、事例、考察
    • 着床前遺伝子診断-新興市場
    • 出生前診断-新しいテクノロジーがチャンスを生み出す
    • 新生児検査
    • 診断検査
    • キャリア検査
    • 予測診断/発症前検査
    • 薬理ゲノミクス
    • 法医学試験
    • 保護者のテスト
    • 祖先のテスト
  • 産業構造
    • 病院の検査シェア
    • 規模の経済
    • 内科医院
    • 医師とPOCT
  • 主要な遺伝学プレーヤーの市場シェア-分析

第3章 市場動向

  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 計装と自動化
  • 診断技術の開発
    • 次世代シーケンシング (NGS):革命の促進
    • NGSの価格設定への影響
    • POCT:創造的破壊的な検査手法
    • 薬理ゲノミクス:診断と治療の一体化
    • CGESテスト:新世界の開拓
    • バイオチップ/巨大磁気抵抗ベースのアッセイ

第4章 遺伝子検査:近年の進捗状況

  • 当セクションの重要性と活用方法

第5章 主要企業のプロファイル

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • シスメックス
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

第6章 世界市場の規模

  • 国別分析:概要
  • 用途別分析:概要
  • 技術別分析:概要

第7章 用途別の市場規模

  • 新生児検査
  • NIPT (非侵襲的出生前遺伝学的検査)
  • 予測検査
  • 腫瘍検査
  • DTC (消費者直結型検査)
  • その他

第8章 遺伝子検査市場:技術別

  • PCR (ポリメラーゼ連鎖はんの) 検査
  • NGS (次世代シーケンシング)
  • 細胞遺伝学的検査
  • その他

第9章 遺伝子検査の将来性

付録

図表

Table of Tables

  • Table 1: Most Common Traditional Genetic Disorders
  • Table 2: Lab Spending 2014 to 2024
  • Table 3: Market Players by Type
  • Table 4: The Different Types of Genetic Tests
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Global Market by Country
  • Table 10: Global Market by Application
  • Table 11: Global Market by Technology
  • Table 12: Newborn Segment by Country
  • Table 13: NIPT Segment by Country
  • Table 14: Predictive Segment by Country
  • Table 15: Oncology Segment by Country
  • Table 16: DTC Segment by Country
  • Table 17: Other Segment by Country
  • Table 18: PCR Segment by Country
  • Table 19: NGS Segment by Country
  • Table 20: Cytogenetic Segment by Country
  • Table 21: Other Segment by Country
  • Table 22: 2020 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Top Ten Sequencing Companies
  • Figure 3: Percentage of World Population Over 65
  • Figure 4: Key Countries
  • Figure 5: Application Share by Year
  • Figure 6: Application Segment Growth Rates
  • Figure 7: Segment Share Shifts
  • Figure 8: Application Segment Share Base Year
  • Figure 9: Application Segment Share Final Year
  • Figure 10: Technology Share by Year
  • Figure 11: Technology Segment Growth Rates
  • Figure 12: Technology Segment Share Shifts
  • Figure 13: Technology Segment Share Base Year
  • Figure 14: Technology Segment Share Final Year
  • Figure 15: Newborn vs. Total Market Growth
  • Figure 16: NIPT vs. Total Market Growth
  • Figure 17: Predictive vs. Total Market Growth
  • Figure 18: Oncology vs. Total Market Growth
  • Figure 19: DTC vs. Total Market Growth
  • Figure 20: Other vs. Total Market Growth
  • Figure 21: PCR vs. Total Market Growth
  • Figure 22: NGS vs. Total Market Growth
  • Figure 23: Cytogenetic vs. Total Market Growth
  • Figure 24: Other vs. Total Market Growth
目次

OVERVIEW:

Large genetic testing cancer segment impacted by COVID-19. Genetic Blizzard creating confusing array of new tests.

Will all newborns receive Whole Genomic Sequencing at birth? What has happened to Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Genetic Testing Definition in This Report
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
    • 1.3.1. Newborn Screening
    • 1.3.2. Non Invasise Pregnancy Testing
    • 1.3.3. Predictive
    • 1.3.4. Oncology
    • 1.3.5. Direct to Consumer
    • 1.3.6. Other Application
    • 1.3.7. PCR
    • 1.3.4. NGS
    • 1.3.5. Cytogenetic
    • 1.3.6. Other Technology
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Supplier/pharmaceutical
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Independent Genetic Testing Lab
    • 2.1.10. Audit Body
  • 2.2. Genetic Tests -Types, Examples and Discussion
    • 2.2.1. Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2. Prenatal Diagnosis-New Technologies Create Opportunity
    • 2.2.3. Newborn Screening
    • 2.2.2. Diagnostic Testing
    • 2.2.3. Carrier Testing
    • 2.2.6. Predictive and Presymptomatic Testing
    • 2.2.7. Pharmacogenomics
    • 2.2.8. Forensic Testing
    • 2.2.9. Parental Testing
    • 2.2.10. Ancestral Testing
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
      • 2.3.2.1. Hospital vs. Central Lab
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2. Aging Population a Boon for Diagnostics
    • 3.1.3. Pharmacogenomics Drives Further Growth.
    • 3.1.4. Oncology and Liquid Biopsy Enter New Era
    • 3.1.5. Fertility Practice Growth drives market
    • 3.1.6. Direct to Consumer begins to break out
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Testing usage analysis curtailing growth.
    • 3.2.4. Wellness has a downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution.
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. POCT/Self Testing Disruptive Force
    • 3.4.4. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5. CGES Testing, A Brave New World
    • 3.4.6. Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1. Importance of This Section
  • 4.1.2. How to Use This Section
    • Preconception Carrier Screening Trial Begins in Australia
    • Genetic Testing Clinical Use Just Beginning
    • Fulgent Genetics Q1 Revenues Jump 44 Percent
    • Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic,
    • Hematologic Disorders
    • Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests
    • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
    • Thermo Fisher Scientific to Buy Qiagen for $11.5B
    • PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England
    • Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study
    • Qiagen, NeuMoDx Ink Partnership, Merger Agreement

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1. Global Market by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart-Key Country Densities
  • 6.2. Global Market by Application
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Application Share by Year
    • 6.2.3. Chart-Application Segment Growth Rates
    • 6.2.4. Chart-Application Segment Share Shifts
    • 6.2.5. Chart-Application Segment Share Base Year
    • 6.2.6. Chart-Application Segment Share Final Year
  • 6.3. Global Market by Technology
    • 6.3.1. Table-Global Market by Technology
    • 6.3.2. Chart-Technology Share by Year
    • 6.3.3. Chart-Technology Segment Growth Rates
    • 6.3.4. Chart-Technology Segment Share Shifts
    • 6.3.5. Chart-Technology Segment Share Base Year
    • 6.3.6. Chart-Technology Segment Share Final Year

7. Market Sizes by Application

  • 7.1. Newborn Testing Market
    • 7.1.1. Table Newborn-by Country
    • 7.1.2. Chart-Newborn Growth
  • 7.2. NIPT Market
    • 7.2.1. Table NIPT-by Country
    • 7.2.2. Chart-NIPT Growth
  • 7.3. Predictive Testing Market
    • 7.3.1. Table Predictive-by Country
    • 7.3.2. Chart-Predictive Growth
  • 7.4. Oncology Testing Market
    • 7.4.1. Table Oncology-by Country
    • 7.4.2. Chart-Oncology Growth
  • 7.5. DTC Testing Market
    • 7.5.1. Table DTC-by Country
    • 7.5.2. Chart-DTC Growth
  • 7.6. Other Testing Market
    • 7.6.1. Table Other-by Country
    • 7.6.2. Chart-Other Growth

8. Global Genetic Testing Market by Technology

  • 8.1. PCR Testing Market
    • 8.1.1. Table PCR-by Country
    • 8.1.2. Chart-PCR Growth
  • 8.2. NGS Market
    • 8.2.1. Table NGS-by Country
    • 8.2.2. Chart-NGS Growth
  • 8.3. Cytogenetic Testing Market
    • 8.3.1. Table Cytogenetic-by Country
    • 8.3.2. Cytogenetic-Predictive Growth
  • 8.4. Other Testing Market
    • 8.4.1. Table Other-by Country
    • 8.4.2. Chart-Other Growth

9. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II Methodology
    • II.1 Authors
    • II.2 Sources
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.